Debio 0532

Debio 0532 program leverages the development of antibodies integrating our linker technologies Multilink™ and AbYlink™, to create innovative antibody drug conjugates (ADCs). These novel ADCs will target tumor-specific antigens to fight cancers with high unmet need, including those tumor types expressing HER2/HER3.